Lipoprotein(a), often overlooked in routine cholesterol tests, is a type of cholesterol that can raise the risk of heart attacks and strokes. In fact, higher levels of Lp(a) are associated with an increased risk of not just heart attacks but also aortic valve disease. Alarmingly, Lp(a) levels are largely determined by genetics—70-90% of the variation is inherited. This means that even those who maintain healthy lifestyles might still be at elevated risk due to genetic factors.

That context matters because traditional cholesterol-lowering medications like statins do not affect Lp(a) levels. This gap has led researchers to explore newer drugs, such as PCSK9 inhibitors, which can lower Lp(a) by 15-30%. These developments bring hope to individuals who may otherwise be left unprotected against cardiovascular threats.

But what about lifestyle factors? Mindfulness training has shown promise in improving heart health as well. In just eight weeks, daily mindfulness practice combined with weekly sessions can lead to measurable improvements in heart health metrics. Studies indicate that mindfulness can reduce systolic blood pressure by an average of 7.6 points—beneficial for anyone concerned about their cardiovascular well-being.

This holistic approach can be complemented by dietary changes as well. For instance, regular consumption of pistachios—a snack enjoyed for over 8,000 years—has been linked to lower LDL cholesterol and blood pressure. A handful contains only 174 calories and packs a protein punch with 6.1 grams per serving.

As we stand on the cusp of these advancements in understanding and treating lipoprotein(a), it raises significant questions about how we will adapt our approaches to heart health moving forward. Will healthcare providers begin incorporating Lp(a) testing into routine assessments? The answers remain unclear.

What’s certain is that the landscape of cardiovascular disease prevention is evolving. With new treatments on the horizon and lifestyle interventions gaining traction, individuals now have more tools than ever to manage their heart health effectively.

The post Heart health: How Could New Treatments for Transform Cardiovascular Risk Management? appeared first on newscasino.

Historically, the focus has been on LDL cholesterol—the so-called ‘bad’ cholesterol. Doctors and researchers believed that lowering LDL levels would reduce the risk of heart attacks. Yet, studies have shown that this isn’t the whole story. Many patients with normal LDL levels still suffer from cardiovascular issues. So what about Lp(a)?

Lp(a) was first discovered in 1963, but it remained largely under the radar until recently. Research indicates that people with high levels of Lp(a) face more than double the risk of heart attack compared to those without elevated levels. An estimated one in five people worldwide has elevated Lp(a). This alarming statistic is prompting pharmaceutical giants like Novartis, Amgen, and Eli Lilly to explore treatments targeting this specific cholesterol.

The decisive moment came when these companies began late-stage trials for drugs aimed at reducing Lp(a) levels. Novartis’ pelacarsen, for instance, aims to lower Lp(a) significantly. Preliminary data suggests that these experimental drugs can slash levels of Lp(a) by more than 80%. That’s a staggering reduction—one that could reshape cardiology as we know it.

What does this mean for patients? If these drugs prove effective in preventing heart attacks, we might see a new era in cardiovascular treatment. However, uncertainties remain. The exact levels of Lp(a) that need to be lowered to prevent heart attacks are still unclear. Additionally, the timeline for results from Novartis’ trial has been delayed due to slower-than-expected occurrences of heart attacks among participants.

Experts are optimistic about this shift. Dr. Steve Nissen notes the importance of keeping an open mind regarding cholesterol management strategies: “We thought raising HDL would be beneficial and that didn’t work, so I think we have to keep an open mind.” Jay Bradner adds that the clarity from population genetics renders this pursuit a smart bet.

As these companies push forward with their trials, they hope at least one drug will succeed—”We hope at least one of them ends up in the back of the net,” says Dr. Nissen. The stakes couldn’t be higher; with cardiovascular disease being a leading cause of death globally, effective treatments are urgently needed.

This emerging focus on Lp(a) could not only lead to substantial financial gains—projected sales could reach $5.6 billion annually by 2032—but also save countless lives by preventing heart attacks before they happen.

The post Cholesterol: Why is , specifically Lp(a), the new focus for heart drug developers? appeared first on newscasino.